İçeriğe geç
akaturk Akademik ölçüm
Giriş yap Kayıt ol

Akademisyen

SEVİM ERDEM ÖZDAMAR

PROFESÖR

HACETTEPE ÜNİVERSİTESİ TIP FAKÜLTESİ DAHİLİ TIP BİLİMLERİ BÖLÜMÜ

Araştırma konuları OpenAlex
Akademik özet YÖKSİS ve OpenAlex ayrı sayılır.
Makale 95
YÖKSİS95 OpenAlex0
Proje 11
Kitap 17
Bildiri 77

Atıf etkisi

OpenAlex YÖKSİS makalelerinden OpenAlex’te eşleşen: 71
h-indeks 20 Türkiye yüzdelik dilimi: 98 Üniversitesinde h-indekse göre 160. / 2.315
i10-indeks
33
Toplam atıf
4.035
Türkiye’de üst %0,5
Makale başına
56,8
FWCI
2,51
1,00 = dünya ortalaması
Dünyada üst %1
4
Dünyada üst %10
14

En çok atıf alan makaleleri

  1. Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis 2006 dünyada üst %1 1.348 atıf
  2. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study 2017 dünyada üst %1 833 atıf
  3. Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis 2019 dünyada üst %1 256 atıf

h-indeks ve atıflar, bu akademisyenin YÖKSİS makalelerinden OpenAlex’te eşleşenlerin atıf sayılarından hesaplanır (Google Scholar, WoS veya Scopus değildir). Eşleşmeyen makalelerin atıfı dahil değildir.

Alan sıralaması

YÖKSİS ?

Dizin çeyrekleri

?
Scopus (SJR) 78
  • Q1 29
  • Q2 24
  • Q3 16
  • Q4 9
WoS (JCR) 78
  • Q1 15
  • Q2 20
  • Q3 25
  • Q4 19
TR Index TR Index

10 makale

OpenAlex atıf yüzdelik
  • Üst %1 4
  • Üst %10 14
  • Ort. 63.0%
  • n 74
Diğer sayımlar

Scopus (SJR)

  • YÖKSİS satırı 81

WoS (JCR)

  • En iyi Q 78 Q1 15 Q2 20 Q3 25 Q4 18
  • YÖKSİS satırı 81

TR Index

  • YÖKSİS satırı 11 makale

Makaleler

YÖKSİS ve OpenAlex kaynak ayrımıyla makaleler; quartile ve TR Index ile daraltabilirsiniz.

Yayını olan dergiler

55 dergi
Scopus (SJR)
Q1 29 Q2 24 Q3 16 Q4 9
WoS (JCR)
Q1 15 Q2 20 Q3 25 Q4 19
TR Index
10 makale

Makale listesi

  1. 2025 Random X chromosome inactivation in female Charcot-Marie-Tooth disease type X1: insights from sural nerve biopsy analysis BMC Neurology DOI 10.1186/s12883-025-04297-z YÖKSİS SJR Q2 JCR Q3 OpenAlex 15.1%
  2. 2025 Adult-onset desmin myopathy in a patient with multiple sclerosis. Ideggyogy Sz . DOI 10.18071/isz.78.0357 YÖKSİS SJR Q4 JCR Q4
  3. 2025 Diagnostic yield of clinical exome sequencing in patients with suspected hereditary neuropathy Turkish Journal of Medical Sciences DOI 10.55730/1300-0144.6105 YÖKSİS TR Index SJR Q3 JCR Q2 OpenAlex 43.3%
  4. 2025 Efficacy and safety of avalglucosidase alfa in patients with late-onset Pompe disease after 145 weeks of treatment during the COMET trial Journal of Neurology DOI 10.1007/s00415-025-13266-y YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %10 OpenAlex 95.6%
  5. 2025 The impact of COVID-19 pandemic on adult individuals with neuromuscular disease Turkish Journal of Neurology DOI 10.55697/tnd.2025.358 YÖKSİS TR Index OpenAlex 28.4%
  6. 2024 Recurrent simultaneous central nervous system demyelination with possible peripheral demyelination / nodopathy in a seronegative patient Ideggyógyászati szemle DOI 10.18071/isz.77.0357 YÖKSİS SJR Q4 JCR Q4 OpenAlex 21.9%
  7. 2024 Effect of Follicular T Helper and T Helper 17 Cells-Related Molecules on Disease Severity in Patients with Myasthenia Gravis European Neurology DOI 10.1159/000540794 YÖKSİS SJR Q3 JCR Q3 OpenAlex 56.7%
  8. 2024 Differentiating recurrent Guillain–Barre syndrome and acute-onset chronic inflammatory polyneuropathy: literature review Acta Neurologica Belgica DOI 10.1007/s13760-024-02557-2 YÖKSİS SJR Q2 JCR Q3 OpenAlex 86.8%
  9. 2024 Clinical and laboratory remission with rituximab in anti-MuSK-positive myasthenia gravis Irish Journal of Medical Science (1971 -) DOI 10.1007/s11845-024-03763-w YÖKSİS SJR Q2 JCR Q2 OpenAlex 76.4%
  10. 2024 Home infusion experience in patients with Pompe disease receiving avalglucosidase alfa during three clinical trials Molecular Genetics and Metabolism DOI 10.1016/j.ymgme.2024.108608 YÖKSİS SJR Q2 JCR Q2 OpenAlex 78.2%
  11. 2023 The evaluation of small fibers in multiple sclerosis Multiple Sclerosis and Related Disorders DOI 10.1016/j.msard.2023.104602 YÖKSİS SJR Q1 JCR Q2 OpenAlex 61.2%
  12. 2023 Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks JAMA Neurology DOI 10.1001/jamaneurol.2023.0552 YÖKSİS SJR Q1 JCR Q1 OpenAlex üst %10 OpenAlex 98.4%
  13. 2023 Nusinersen for adults with spinal muscular atrophy Neurol Sci DOI 10.1007/s10072-023-06698-9 YÖKSİS SJR Q1 JCR Q2 OpenAlex üst %10 OpenAlex 93.0%
  14. 2023 Expert opinion on the diagnostic odyssey and management of late-onset Pompe disease: a neurologists perspective Frontiers ın Neurology DOI 10.3389/fneur.2023.1095134 YÖKSİS SJR Q2 JCR Q2 OpenAlex 84.8%
  15. 2022 Autologous Stem Cell Transplantation in a Patient with Refractory Anti‑MuSK‑Positive Myasthenia Gravis and Familial Mediterranean Fever Neurological Sciences and Neurophysiology DOI 10.4103/nsn.nsn_197_21 YÖKSİS TR Index SJR Q4 JCR Q4 OpenAlex 65.1%
  16. 2022 Comprehensive evaluation of velopharyngeal function in myasthenia gravis patients Acta Neurologica Belgica DOI 10.1007/s13760-022-01904-5 YÖKSİS SJR Q2 JCR Q3 OpenAlex 64.8%
  17. 2022 The functional and structural evaluation of small fibers in asymptomatic carriers of p. Val50Met mutation NEUROMUSCULAR DISORDERS YÖKSİS SJR Q1 JCR Q3
  18. 2022 Multimodal assessment of intensive care unit-acquired weakness in severe stroke patients Acta Neurologica Belgica DOI 10.1007/s13760-022-02009-9 YÖKSİS SJR Q2 JCR Q3 OpenAlex 67.1%
  19. 2022 Two distinct skeletal muscle microRNA signatures revealing the complex mechanism of sporadic ALS Acta Neurologica Belgica DOI 10.1007/s13760-021-01743-w YÖKSİS SJR Q2 JCR Q3 OpenAlex 59.4%
  20. 2022 Identifying A Cut-Off Point for Timed Up and Go Test in Neuromuscular Diseases Turkish Journal Of Neurology DOI 10.4274/tnd.2021.84553 YÖKSİS TR Index SJR Q4 JCR Q4 OpenAlex 26.1%

Akademisyenlere dön